Locoregional Therapy Is Reentering the Conversation in Advanced Intrahepatic Cholangiocarcinoma
Advanced intrahepatic cholangiocarcinoma rarely presents as a purely local disease for long. Once curative resection is no longer feasible, the tumor often remains liver-confined or at least liver-dominant for a meaningful stretch of the disease course, which makes locoregional treatment biologically plausible and clinically attractive. At the same time, occult or overt extrahepatic spread still demands systemic control, and that duality is what now frames treatment planning in this setting.
A narrative review published in 2026 brings together the newest clinical and mechanistic evidence for combining locoregional therapy with chemotherapy, immune checkpoint blockade, molecularly targeted agents, and cellular therapy. The central message is straightforward: the field has enough momentum to justify combination strategies, but not enough mature comparative evidence to treat any particular locoregional approach as a standard addition for all patients with advanced disease.
Systemic Therapy Has Improved, but the Survival Gain Remains Modest
First-line treatment for biliary tract cancers has shifted with randomized phase III data supporting gemcitabine-cisplatin paired with durvalumab or pembrolizumab. Yet the magnitude of benefit in the primary analyses remains small, with median overall survival gains of 1.3 months and 1.8 months, respectively. In a disease where progression often reflects both intrahepatic burden and microscopic dissemination, those gains matter, but they also leave substantial room for better disease control inside the liver.
The biologic logic for adding locoregional therapy follows directly from that gap. Local treatment can debulk dominant hepatic disease, reduce viable tumor burden, and potentially alter the inflammatory and immunologic milieu within the liver. In theory, that could complement systemic therapy by slowing local escape while the systemic backbone addresses disease beyond the liver. In practice, the quality of evidence still trails the strength of the rationale.
The survival gains from first-line immunochemotherapy leave a large unmet need inside the liver.
Yttrium-90, Infusion Therapy, Radiation, and Cryoablation Show Activity Without Definitive Comparators
Prospective single-arm studies have reported activity for several locoregional approaches when they are layered onto systemic treatment or deployed in selected intrahepatic cholangiocarcinoma populations. Yttrium-90 radioembolization, hepatic arterial infusion, radiotherapy, and cryoablation-based combinations all appear in this literature, but the studies are heterogeneous in design, patient selection, and treatment sequencing. Many lack a contemporary control arm, which makes it impossible to separate the effect of the locoregional modality from the effect of the systemic regimen, patient enrichment, or natural variation in disease biology.
That limitation is especially important in a disease with wide clinical heterogeneity. A patient with bulky liver-dominant disease behaves differently from a patient with early extrahepatic spread, and a combination strategy that seems promising in one subgroup may simply reflect selection of patients with more favorable tumor biology. Without direct comparative data, the apparent signal of benefit remains difficult to interpret.
Still, the consistent theme across these studies is not trivial. The liver remains the dominant disease reservoir in many cases of advanced ICC, and therapies that attack hepatic lesions directly may be the only way to meaningfully compress tumor burden when surgery is off the table. The challenge is proving that the improvement is durable, reproducible, and worth the added toxicity and procedural complexity.
Biomarkers Have Not Yet Identified Who Benefits Most
No biomarker has validated the incremental benefit of a specific locoregional therapy. That absence leaves clinicians without a reliable way to predict which tumors are most likely to respond to a liver-directed intervention versus which are already biologically too disseminated for local treatment to matter.
This gap has practical consequences. Without molecular or immune markers that distinguish responders from nonresponders, treatment selection still rests on disease distribution, hepatic reserve, prior therapy, procedural feasibility, and institutional expertise. A biomarker-guided approach would be especially valuable in ICC, where molecular alterations can inform systemic therapy choices, but no parallel marker has yet defined the best locoregional partner.
The review’s framing reflects a larger truth about the disease. A local therapy can only do so much if the biology is already systemic, and even a potent systemic regimen may not fully control a liver packed with active tumor deposits. Effective combination treatment will likely require both an anatomic fit and a biologic fit.
Cellular Therapy Raises the Bar for Precision but Also for Trial Design
Emerging cellular therapy adds another layer of complexity. Its inclusion in the review signals how quickly the therapeutic conversation is expanding beyond conventional chemotherapy and immunotherapy. Yet cellular approaches are likely to demand even sharper patient selection, more explicit safety monitoring, and tighter integration with existing systemic backbones than older locoregional modalities.
For advanced ICC, that means future studies cannot remain vague about what is being tested. Trial design needs to specify the locoregional therapy modality, the dose or exposure, the pattern of disease distribution, the systemic backbone, the treatment intent, and the safety boundary. Without those details, the field will continue to accumulate small, difficult-to-compare studies that offer suggestive signals but not enough certainty for routine practice.
Even the most attractive biologic rationale fails if the trial architecture is too loose to interpret. In a disease where progression can be rapid and mixed in pattern, every sequence decision matters: whether the liver-directed procedure comes before, after, or alongside systemic therapy, and whether the patient is being treated for cytoreduction, consolidation, or palliation.
What Future Studies Need to Prove
Routine adoption of combination strategies will require reproducible protocols, comparative survival and safety endpoints, and paired biomarker collection. Those requirements are not academic formalities; they are the minimum needed to understand whether a particular locoregional strategy genuinely adds benefit or simply concentrates treatment burden without changing outcomes.
The next generation of studies should be built around clear clinical questions. Which patients have liver-dominant disease enough to justify a locoregional escalation? Which systemic backbone gives the best platform for combination? Which safety profile is acceptable when hepatic reserve is already under strain? And which biomarker, if any, can identify the subgroup where the added intervention truly shifts the course of disease?
For now, the evidence supports cautious interest rather than broad adoption. Advanced intrahepatic cholangiocarcinoma remains a disease in which local and systemic control both matter, but the data are not yet mature enough to define a universal combination standard.